Cecile Guegan was named Chief Financial Officer of Pfizer Inc, effective November 1, 2026. As of November 6, 2026, Pfizer Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 18, 2026 to November 3, 2026, naming 2 appointments and 1 departure (Form 8-K, November 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pfizer Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pfizer Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-18 to 2026-11-03. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Pfizer Inc files it.
Also on the record for Pfizer Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 1, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.51% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pfizer Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Pfizer Inc and the records around it.
Pfizer Inc elsewhere on the record
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Pfizer Inc
Get an email when Pfizer Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pfizer Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pfizer Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pfizer Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | In | Chief Financial Officer | 2026-11-01 | 8-K, 2026-11-03 | |
| 2026-06-18 | Out | Chief Financial Officer | 2026-08-15 | 8-K, 2026-06-18 | |
| 2026-06-18 | In | Chief Financial Officer | 2026-08-16 | 8-K, 2026-06-18 |
Who leads Pfizer Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Cecile Guegan, appointed, effective 2026-11-01 (filed 2026-11-03).
New leaders reset buying decisions — get the Full Report on Pfizer Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Pfizer Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Pfizer IncEvery change, in the filing's words
Appointed: Cecile Guegan, Chief Financial Officer, effective 2026-11-01
On November 3, 2026, Pfizer Inc. (the "Company") announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the "Effective Date").
- Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry.
- She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses.
- At Pfizer, she has held successive finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group.
- Immediately before her appointment as Interim Chief Financial Officer, she served as Senior Vice President of Finance for Pfizer's Global Biopharmaceuticals business since 2022 and Vice President, Finance, Research & Development and Business Office from 2020 to 2022.
- Ms. Guegan holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF).
- In connection with Ms. Guegan's election, the Compensation Committee of the Board of Directors of the Company unanimously approved the following compensation arrangements for Ms. Guegan as of the Effective Date: (1) an annual base salary of $1,300,000; and (2) an annual target cash incentive opportunity of $1,300,000, which represents 100% of her annual base salary, which will be determined based on the salary paid during the year.
Departing: Dave Denton, Chief Financial Officer, effective 2026-08-15
On June 16, 2026, Dave Denton notified Pfizer Inc. (the "Company") that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company's financial or operating results or to any disagreements with the Company regarding the Company's financial, operational, accounting or reporting policies or practices.
Appointed: Cecile Guegan, Chief Financial Officer, effective 2026-08-16
In connection with Mr. Denton's departure, the Company announced that Cecile Guegan, the Company's Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton's successor.
- Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022.
- Previously, Ms. Guegan served in various leadership roles within Pfizer's finance organization, including as Vice President, Finance, Research & Development and Business Office from 2020 to 2022.
Tools for this story
Each opens in a new tab, filled in for Pfizer Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.